Skip to main content
SpringerLink
Log in

Rauwolfia derivatives and breast cancer: how do we know when we have the answers?

  • Conference paper
Drugs between Research and Regulations

  • 40 Accesses

Abstract

The problem of combining results from different centres or different experiments is faced by biometricians of the pharmaceutical industry and their clinical colleagues every day. Pressures on limited resources, even in diseases with high incidence or morbidity, have long made the multicentre trial an unwelcome methodological fixture. A great deal more could still be said about the strengths and weaknesses of the techniques used to make the inferences from n patients spread among m centres as strong as — or stronger than — those from nm patients treated in a single centre. A problem that, although it has some properties in common with those of the multicentre trial, seems to have received rather less attention or even to have been almost entirely neglected by some of those whom it most concerns is the combination of information from studies that are spread out not only in space but also in time.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Armstrong B, Skegg D, White G, Doll R (1976) Rauwolfia derivatives and breast cancer in hypertensive women. Lancet 11: 8–12

    Article  Google Scholar 

  2. Armstrong B, Stevens N, Doll R (1974) Retrospective study of the association between use of rauwolfia derivatives and breast cancer. Lancet 11: 672–675

    Article  Google Scholar 

  3. Aromaa A, Hakama M, Hakulinen T, Saxen E, Teppo L, Idänpään-Heikkilä J (1976) Breast cancer and use of rauwolfia and other antihypertensive agents in hypertensive patients: a nation-wide case-control study in Finland. Internat J Cancer 18: 727–738

    Article  CAS  Google Scholar 

  4. Boston Collaborative Drug Surveillance Program (1974) Reserpine and breast cancer. Lancet 11: 669–671

    Google Scholar 

  5. Christopher LJ, Crooks J, Davidson JF, Erskine ZG, Gallon SC, Moir DC, Weir RD (1977) A multicentre study of rauwolfia derivatives and breast cancer. Eur J Clin Pharmacol 11: 409–417

    Article  PubMed  CAS  Google Scholar 

  6. Curb JD, Hardy RD, Labarthe DR, Borhani NO, Taylor JO (1982) Reserpine and breast cancer in the Hypertension Detection and Follow-Up program. Hypertension 4: 307–311

    Article  PubMed  CAS  Google Scholar 

  7. Department of Health, Education, and Welfare (1978) Report of the Ad Hoc Committee on Reserpine and Breast Cancer—Action Report (May 25, 1978 ). Washington DC, DHEW

    Google Scholar 

  8. Farber MD, Detels R (1977) Breast cancer and reserpine use in a population of hypertensive and normotensive women. Am J Epidemiol 106: 238

    Google Scholar 

  9. Federal Register (1983) Professional labelling for reserpine drugs: revised labelling. 48: 14048–14050

    Google Scholar 

  10. Friedman GD (1983) Rauwolfia and breast cancer: no relation found in long term users aged 50 and over. J Chron Dis 36: 367–370

    Article  PubMed  CAS  Google Scholar 

  11. Hammond KR, Joyce CRB (1977) Psychological influences on human judgement, especially of adverse reactions. In: Drug Monitoring. Gross FH, Inman WHW (eds) pp 269–278 Academic Press, London

    Google Scholar 

  12. Heinonen OP, Shapiro S, Tuominen L, Turunen MI (1974) Reserpine use in relation to breast cancer. Lancet 11: 675–677

    Article  Google Scholar 

  13. Henderson M (1977) Reserpine and breast cancer — a review. In: Colombo F, Shapiro S, Slone D, Tognoni G (eds) Epidemiological Evaluation of Drugs. Proceedings of the International Symposium on Epidemiological Evaluation of Drugs, Milan, 2–4 May, 1977 Amsterdam, Elsevier/North Holland Biomedical Press

    Google Scholar 

  14. Hogarth R (1980) Judgement and Choice. Wiley, Chichester

    Google Scholar 

  15. Hulka B (1984) When is the evidence for “no association” sufficient? JAMA 252: 81–82

    Article  PubMed  CAS  Google Scholar 

  16. Hypertension Detection and Follow-up Program Cooperative Group (1979) Five year findings of the hypertension detection and follow-up program. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 242: 2562–2571

    Article  Google Scholar 

  17. International Agency for Research on Cancer (1980) Evaluation of the Carcinogenic Risk of Chemicals to Humans. IARC Monog 24: 211–241

    Google Scholar 

  18. Jesdinsky HJ (1984) Pooling trial results. Society for Clinical trials 5th Annual Meeting, Miami, Florida, p 49

    Google Scholar 

  19. Jus A, Fabia J, Bernard P-M, Jus K (1976) Reserpine and breast cancer: a retrospective cohort study. Unpublished manuscript pp 12 (see also Jus A et al., Am J Psychiat 133: 451–452

    PubMed  CAS  Google Scholar 

  20. Kewitz H, Jesdinsky HJ, Schröter P-M, Lindtner E (1977): Reserpine and breast cancer in women in Germany. Eur J Clin Pharmacol 11: 79–83

    Article  PubMed  CAS  Google Scholar 

  21. Kodlin D, McCarthy N (1978) Reserpine and breast cancer. Cancer 41: 761–768

    Article  PubMed  CAS  Google Scholar 

  22. Labarthe DR (1979) Methodologie variation in case-control studies of reserpine and breast cancer. J Chron Dis 32: 95–104

    Article  PubMed  CAS  Google Scholar 

  23. Labarthe DR, O’Fallon WM (1980) A community-based longitudinal study of 2,000 hypertensive women. JAMA 243: 2304–2310

    Article  PubMed  CAS  Google Scholar 

  24. Laska EM, Siegel C, Meisner M, Fischer S, Wanderling J (1975) Matched-pairs study of reserpine use and breast cancer. Lancet 11: 296–300

    Article  Google Scholar 

  25. Lilienfeld AM, Chang L, Thomas DB, Levin ML (1975) Rauwolfia derivatives and breast cancer. Johns Hopkins Med J 139: 41–50

    Google Scholar 

  26. Mack TM, Henderson BE, Gerkins VR, Arthur M, Baptista J, Pike MC (1975) Reserpine and breast cancer in a retirement community. New Engl J Med 292: 1366–1371

    Article  PubMed  CAS  Google Scholar 

  27. Management Committee (1980) The Australian Therapeutic Trial in Mild Hypertension. Lancet 1: 1261–1267

    Google Scholar 

  28. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Nat Cancer Inst 252: 719–748

    Google Scholar 

  29. Miller ST, Runyan JW (1975) Absence of association between rauwolfia alkaloids and breast cancer. J Tenn Med Ass 68: 657–658

    Google Scholar 

  30. Moriwaki S, Takashima S, Fukuda K (1978) Relationship between breast cancer and blood pressure as well as hypotensors. Clin Aspects Cancer 24: 98–101

    Google Scholar 

  31. Moser M (1977) Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure: A Cooperative Study. JAMA 237: 255–261

    Article  Google Scholar 

  32. O’Fallon WM, Labarthe DR, Kurland LT (1975) A case-control study in Olmsted County, Minnesota. Lancet 11: 292–296

    Google Scholar 

  33. O’Neill RT, Anello C (1978) Case-control studies: a sequential approach. Am J Epidem 108: 415

    Google Scholar 

  34. Shapiro S, Parsells JL, Rosenberg L, Kaufman DW, Stolley PD, Schottenfeld D (1984) Risk of breast cancer in relation to the use of rauwolfia alkaloids. Eur J Clin Pharmacol 26: 143–146

    Article  PubMed  CAS  Google Scholar 

  35. Simpson FO (1975) Rauwolfia and breast cancer. NZ Med J 82: 138

    Google Scholar 

  36. Takatani O, Kuno K, Yoshida Y, Terasawa T, Fujimori M (1978) Clinical epidemiological studies on reserpine use in relation to breast cancer among Japanese women. Proc Jap Cancer Ass 37: 283

    Google Scholar 

  37. Veterans Administration Cooperative Study Group on Antihypertensive Agents (1977) Propranolol in the treatment of hypertension. JAMA 237: 2303–2310

    Article  Google Scholar 

  38. Watanuki T (1977) Analysis of answers to the questionnaire on breast cancer and reserpine. J Jap Soc Treat Cancer 12: 123–124

    Google Scholar 

  39. Williams RR, Feinleib M, Connor RJ, Stegens NL (1978) Case-control study of anti-hypertensive and diuretic use by women with malignant and benign breast lesions detected in a mammography screening program. J Nat Cancer Inst 61: 327–335

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Department, Ciba-Geigy AG, CH-4002, Basel, Switzerland

    Dr. C. R. B. Joyce

Authors
  1. Dr. C. R. B. Joyce
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. ICI-Pharma Arzneimittelwerk Plankstadt, Postfach 10 31 09, D-6900, Heidelberg, Germany

    C. Steichele (Medizinischer Direktor) (Medizinischer Direktor)

  2. Boehringer Mannheim GmbH, Sandhofer Straße 116, D-6800, Mannheim 31, Germany

    U. Abshagen (Leiter Produktentwicklung Therapeutica) (Leiter Produktentwicklung Therapeutica)

  3. F. Hoffmann-La Roche & Co. Ltd., CH-4002, Basel, Switzerland

    J. Koch-Weser M. D. (Director of Clinical Research) (Director of Clinical Research)

Rights and permissions

Reprints and permissions

Copyright information

© 1985 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Joyce, C.R.B. (1985). Rauwolfia derivatives and breast cancer: how do we know when we have the answers?. In: Steichele, C., Abshagen, U., Koch-Weser, J. (eds) Drugs between Research and Regulations. Steinkopff, Heidelberg. https://doi.org/10.1007/978-3-642-54130-8_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-54130-8_13

  • Publisher Name: Steinkopff, Heidelberg

  • Print ISBN: 978-3-642-54132-2

  • Online ISBN: 978-3-642-54130-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation